TrialHaematologica2020

Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study.

Lene Kongsgaard Nielsen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.